A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

~27 mi. (Sassuolo, Italy, +144 more cities)

GSK Investigational Site

Endometrial Carcinoma

carboplatin, +3 more drugs

chemotherapy, +2 more types

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

~29 mi. (Reggio nell'Emilia, Italy, +122 more cities)

AUSL-IRCCS di Reggio Emilia

Prostate Adenocarcinoma

radium Ra 223 dichloride

radiation therapy

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

~29 mi. (Reggio nell'Emilia, Italy, +115 more cities)

Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

~29 mi. (Reggio nell'Emilia, Italy, +179 more cities)

AUSL-IRCCS di Reggio Emilia; Oncologia Medica

Esophageal Squamous Cell Carcinoma

atezolizumab, +1 more drug

immunotherapy

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

~29 mi. (Reggio nell'Emilia, Italy, +64 more cities)

IRCCS A.O. S.Maria Nuova

ER Positive, +1 more biomarker

Breast Carcinoma

anastrozole, +2 more drugs

hormone therapy

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~29 mi. (Reggio nell'Emilia, Italy, +120 more cities)

Arcispedale Santa Maria Nuova

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

~29 mi. (Reggio nell'Emilia, Italy, +108 more cities)

Arcispedale Santa Maria Nuova

BCR-ABL1 Fusion, +1 more biomarker

Acute Lymphoblastic Leukemia

cytarabine, +5 more drugs

chemotherapy, +2 more types

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

~29 mi. (Reggio nell'Emilia, Italy, +18 more cities)

RCCS- Arcispedale Santa Maria Nuova

EGFR A763_Y764insFQEA, +11 more biomarkers

Non-Small Cell Lung Carcinoma

dacomitinib, +1 more drug

targeted therapy

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

~29 mi. (Reggio nell'Emilia, Italy, +13 more cities)

AUSL-IRCCS di Reggio Emilia

Prostate Adenocarcinoma

radium Ra 223 dichloride

radiation therapy

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~34 mi. (Parma, Italy, +383 more cities)

Azienda Ospedaliero Universitaria di Parma

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

~34 mi. (Parma, Italy, +153 more cities)

Azienda Ospedaliero Universitaria di Parma

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

~34 mi. (Parma, Italy, +206 more cities)

Azienda Ospedaliero Universitaria di Parma

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Non-Small Cell Lung Carcinoma

atezolizumab, +1 more drug

immunotherapy